CoChat
Sign Up
Cited by 222Multiple Myeloma Research and TreatmentsProtein Degradation and InhibitorsBone health and treatments

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease

Open access
Lacy, Martha Q., Allred, Jacob B., Gertz, Morie A., Hayman, Suzanne R., Short, Kristen Detweiler, Buadi, Francis, Dispenzieri, Angela, Kumar, Shaji, Greipp, Philip R., Lust, John A., Russell, Stephen J., Dingli, David, Zeldenrust, Steven, Fonseca, Rafael, Bergsagel, P. Leif, Roy, Vivek, Stewart, A. Keith, Laumann, Kristina, Mandrekar, Sumithra J., Reeder, Craig, Rajkumar, S. Vincent, Mikhael, Joseph R.·2011·Blood
DOI 10.1182/blood-2011-04-348896PMC PMC3291492
Open this paper in CoChat — free account

Abstract

Pomalidomide at doses of 2 or 4 mg/d has demonstrated excellent activity in patients with multiple myeloma (MM). We opened 2 sequential phase 2 trials using the pomalidomide with weekly dexamethasone (Pom/dex) regimen at differing doses to study the efficacy of this regimen in patients who have failed both lenalidomide and bortezomib. Pomalidomide was given orally 2 or 4 mg daily with dexamethasone 40 mg weekly. Thirty-five patients were enrolled in each cohort. Confirmed responses in the 2-mg cohort consisted of very good partial response (VGPR) in 5 (14%), partial response (PR) in 4 (11%), minor response (MR) in 8 (23%) for an overall response rate of 49%. In the 4-mg cohort, confirmed responses consisted of complete response (CR) in 1 (3%), VGPR in 3 (9%), PR in 6 (17%), MR in 5 (14%) for an overall response rate of 43%. Overall survival at 6 months is 78% and 67% in the 2- and 4-mg cohort, respectively. Myelosuppression was the most common toxicity. This nonrandomized data suggests no advantage for 4 mg over the 2 mg daily. Pomalidomide overcomes resistance in myeloma refractory to both lenalidomide and bortezomib. This trial is registered at http://ClinicalTrials.gov, number NCT00558896.

Overview

Integrity signals

Registry

Crossref · 10.1182/blood-2011-04-348896

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 9 references

Research works printed but not linked: 1

  1. Kumar, 2009, Natural history of multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter International Myeloma Working Group Study [abstract]., Blood (ASH Annual Meeting Abstracts), 114

Cited by

Sorted by citations

Items 201–222 of 222

Related

See all

Metadata

Authors
Lacy, M. Q., Allred, J. B., Gertz, M. A., Hayman, S. R., Short, K. D., Buadi, F., Dispenzieri, A., Kumar, S., Greipp, P. R., Lust, J. A., Russell, S. J., Dingli, D., Zeldenrust, S., Fonseca, R., Bergsagel, P. L., Roy, V., Stewart, A. K., Laumann, K., Mandrekar, S. J., Reeder, C., Rajkumar, S. V., & Mikhael, J. R.
Affiliations
  • Mayo Clinic (US)
  • Mayo Clinic Arizona, Scottsdale, AZ; and
  • Mayo Clinic in Arizona (US)
  • Mayo Clinic in Florida (US)
ORCID
Venue
Blood
Publisher
American Society of Hematology
Published
2011-09-15
Volume
118
Issue
11
Pages
2970-2975
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
DOI
10.1182/blood-2011-04-348896
PMC
PMC3291492
OpenAlex
W1973888964
Cited by
222
References
9
Citations by year
2026: 3 · 2025: 3 · 2024: 5 · 2023: 3 · 2022: 10 · 2021: 2 · 2020: 5 · 2019: 4 · 2018: 10 · 2017: 17 · 2016: 15 · 2015: 22 · 2014: 31 · 2013: 51 · 2012: 29
FWCI
26.69
Type
journal article
Language
en
Open access
Locations
  • Blood (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Mayo Clinic
  • Celgene
  • National Institute on Aging (R01AG020686)
  • National Cancer Institute (R01CA133966, R01CA136671)
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
  • Health Sciences › Medicine › Oncology › Bone health and treatments
Keywords
pomalidomide, dexamethasone, multiple myeloma, lenalidomide-refractory myeloma, dosing regimen, myelosuppression, overall response rate, overall survival
MeSH terms
Bortezomib, Lenalidomide, Administration, Oral, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Boronic Acids, Dexamethasone, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Multiple Myeloma, Pyrazines, Thalidomide, Survival Analysis, Treatment Outcome, Treatment Failure, Drug Resistance, Neoplasm

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review